DBP International AB: a new patent for SA-033 is granted in Japan
Double Bond Pharmaceutical's forth patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology platform has been granted in Japan. Patent approval provides protection for the treatment method and the design of composition for DBP's front-line product SA-033.
"We are very pleased because it is an important milestone in the development of balanced product pipeline", - comments Igor Lokot, CEO of DBP.
More about SA-033: SA-033 is the first drug candidate that DBP has developed using its innovative drug delivery technology BeloGal®. Due to innovative formulation controls targeting of doxorubicin to the liver, the concentration of the active substance in the desired target organ increases, which enhances efficacy and reduces the toxic side effects that are common in systemic chemotherapy.
More about BeloGal®: BeloGal® is DBP’s innovative drug-delivery platform which targets pharmaceutically active compounds to lung or liver. Video presentation: https://youtu.be/2PKi51PW75Q
This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 07-02-2022 08:30 CET.
